← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Invesco Biotechnology & Genome ETF PBE $431M	86	-1	-1%	$171M
27	BLCM 27 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	81	+10	+14%	$334M
28	28 Lineage Cell Therapeutics LCTX $246M	80	+11	+16%	$113M
29	29 Atara Biotherapeutics ATRA $92.6M	74	+21	+40%	$696M
30	30 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	66	+2	+3%	$15.3M
31	31 Arbutus Biopharma ABUS $850M	63	-14	-18%	$442M
32	AGTC 32 DELISTED Applied Genetic Technologies Corporation AGTC	63	+4	+7%	$143M
33	NSTG 33 DELISTED NanoString Technologies, Inc. NSTG	62	+1	+2%	$231M
34	34 Veracyte VCYT $3.64B	60	+12	+25%	$172M
35	NVTA 35 DELISTED Invitae Corporation NVTA	55	+3	+6%	$276M
36	36 uniQure QURE $1.49B	53	+12	+29%	$207M
37	SIOX 37 DELISTED Sio Gene Therapies Inc. Common Stock SIOX	52	+52	–	$1.99B
38	ADAP 38 DELISTED Adaptimmune Therapeutics ADAP	45	+45	–	$384M
39	39 Abeona Therapeutics ABEO $269M	42	+30	+250%	$21.3M
40	ATHX 40 DELISTED Athersys, Inc. Common Stock ATHX	41	-12	-23%	$9.25M
41	41 DELISTED Carisma Therapeutics CARM	41	-10	-20%	$40M
42	42 Fortress Biotech FBIO $64.7M	41	-8	-16%	$28.5M
43	43 Lakefront Biotherapeutics American Depositary Shares LKFT $1.97B	41	+41	–	$453M
44	44 Cellectis CLLS $111M	40	-4	-9%	$238M
45	45 Fate Therapeutics FATE $231M	39	+14	+56%	$117M
46	46 Vericel Corp VCEL $2.12B	38	+3	+9%	$38.5M
47	47 ProQR Therapeutics PRQR $207M	37	-1	-3%	$181M
48	48 Opus Genetics IRD $332M	35	0	0%	$5.36M
49	49 Pluri PLUR $12.1M	30	-2	-6%	$12.8M
50	50 Neurogene NGNE $479M	27	+2	+8%	$27.5M